Survival Up With Enfortumab Vedotin + Pembrolizumab in Urothelial Cancer
Significantly longer progression-free and overall survival seen in patients with previously untreated locally advanced or metastatic urothelial carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.